<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is a common <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> that increases the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> by 4.5 times </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="3" ids="50249">Anticoagulant</z:chebi>/antithrombotic therapy in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> has been inconsistent and inappropriate </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> enjoyed the monopoly of being the primary medication used to reduce the risk of <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> has many limitations in its use as an ideal <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>To overcome this difficulty, now there are two main alternative groups to <z:chebi fb="8" ids="10033">warfarin</z:chebi> namely, direct thrombin inhibitors (ximelagatran and dabigatran) and factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, etc.) </plain></SENT>
<SENT sid="5" pm="."><plain>The advantages of the newer <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> over the conventional <z:chebi fb="8" ids="10033">warfarin</z:chebi> are numerous </plain></SENT>
<SENT sid="6" pm="."><plain>There are three landmark trials which have shown some light to the path of newer <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> era, which include the following: RE-LY, ROCKET AF and ARISTOTLE </plain></SENT>
<SENT sid="7" pm="."><plain>Head to head comparison of <z:chebi fb="8" ids="10033">warfarin</z:chebi> with newer <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> showed the superiority of newer <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> over <z:chebi fb="8" ids="10033">warfarin</z:chebi> in terms of efficacy and favorable side effect profile </plain></SENT>
<SENT sid="8" pm="."><plain>After few decades of using <z:chebi fb="8" ids="10033">warfarin</z:chebi>, it's high time to enter into the era of newer <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> and bid adieu to <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
</text></document>